M A Pfeffer

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Cardiac function and heart failure
    Marc A Pfeffer
    Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 42:390-2. 2003
  2. ncbi Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 349:1893-906. 2003
  3. ncbi Pharmacologic advances in long-term heart failure management
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am Heart Hosp J 2:15-20. 2004
  4. ncbi Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project
    Marc A Pfeffer
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 105:2341-6. 2002
  5. ncbi Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
    M A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Renin Angiotensin Aldosterone Syst 1:S41-3. 2000
  6. ncbi Statins: a brief summary
    M A Pfeffer
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cardiol 24:II-18. 2001
  7. ncbi Valsartan in acute myocardial infarction trial (VALIANT): rationale and design
    M A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 140:727-50. 2000
  8. ncbi Anemia treatment in chronic kidney disease: shifting uncertainty
    Marc A Pfeffer
    Harvard Medical School, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Heart Fail Rev 13:425-30. 2008
  9. ncbi Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
  10. ncbi A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
    Marc A Pfeffer
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2019-32. 2009

Detail Information

Publications117 found, 100 shown here

  1. ncbi Cardiac function and heart failure
    Marc A Pfeffer
    Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 42:390-2. 2003
  2. ncbi Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 349:1893-906. 2003
    ..In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients...
  3. ncbi Pharmacologic advances in long-term heart failure management
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am Heart Hosp J 2:15-20. 2004
    ..This challenge is currently being addressed with aldosterone blocking agents as well as angiotensin receptor blockers. This article discusses the major RCTs in this field and places the new trials in perspective...
  4. ncbi Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project
    Marc A Pfeffer
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 105:2341-6. 2002
    ..Therapeutic decisions regarding pharmacological therapy should be based on safety and tolerability as well as efficacy data. Clinical trials designed to assess efficacy are often insufficiently powered to generate reliable safety data...
  5. ncbi Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
    M A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Renin Angiotensin Aldosterone Syst 1:S41-3. 2000
    ..VALIANT, with its three arms targetting 14,500 patients, is uniquely poised to determine whether the pharmacological advance in the development of ARBs confers additional clinical (survival) value in high risk MI patients...
  6. ncbi Statins: a brief summary
    M A Pfeffer
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cardiol 24:II-18. 2001
    ..Both monotherapy and combination statin regimens are being studied to optimize treatment of the total patient and to assess mechanisms and benefits of various components of the total lipid profile...
  7. ncbi Valsartan in acute myocardial infarction trial (VALIANT): rationale and design
    M A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 140:727-50. 2000
    ..The development of angiotensin II receptor blockers offers a new, more specific, and theoretically more complete pharmacologic mode to inhibit the adverse influence of angiotensin II...
  8. ncbi Anemia treatment in chronic kidney disease: shifting uncertainty
    Marc A Pfeffer
    Harvard Medical School, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Heart Fail Rev 13:425-30. 2008
    ..This review will outline the importance of having a placebo-controlled trial in this patient population to better assess the risk benefit profile of this therapy...
  9. ncbi Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
    ..Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and morbidity...
  10. ncbi A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
    Marc A Pfeffer
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2019-32. 2009
    ..Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested...
  11. ncbi Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Kidney Dis 54:59-69. 2009
    ....
  12. ncbi Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    David Aguilar
    Cardiovascular Division, University of Texas Health Science Center, 6431 Fannin, MSB 1 246, Houston, TX 77030, USA
    Circulation 110:1572-8. 2004
    ..A prior diagnosis of diabetes mellitus is associated with adverse outcomes after acute myocardial infarction (MI), but the risk associated with a new diagnosis of diabetes in this setting has not been well defined...
  13. ncbi Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
    F M Sacks
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass, USA
    Circulation 97:1446-52. 1998
    ..Although LDL lowering has been shown to reduce recurrent coronary events in patients with coronary heart disease, little direct information is available on the extent of LDL lowering required to achieve this outcome...
  14. ncbi Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction
    Nagesh S Anavekar
    Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115, USA
    N Engl J Med 351:1285-95. 2004
    ..12), which was independent of the treatment assignment. CONCLUSIONS: Even mild renal disease, as assessed by the estimated GFR, should be considered a major risk factor for cardiovascular complications after a myocardial infarction...
  15. ncbi Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience
    Kent Stephenson
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Heart Rhythm 4:308-13. 2007
    ....
  16. ncbi Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators
    P M Ridker
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 98:839-44. 1998
    ..We studied whether inflammation after myocardial infarction (MI) is a risk factor for recurrent coronary events and whether randomized treatment with pravastatin reduces that risk...
  17. ncbi Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial
    M A Pfeffer
    Brigham and Women s Hospital, Boston, Mass, USA
    Circulation 95:2643-51. 1997
    ..Although ACE inhibitor therapy has been shown to reduce mortality in patients with acute myocardial infarction (MI), the optimal dose and the timing of its initiation have not been determined...
  18. ncbi Left ventricular remodeling and ventricular arrhythmias after myocardial infarction
    Martin St John Sutton
    Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 107:2577-82. 2003
    ....
  19. ncbi Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement
    G F Mitchell
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 96:4254-60. 1997
    ..There is increasing evidence of a link between conduit vessel stiffness and cardiovascular events, although the association has never been tested in a large post-myocardial infarction patient population...
  20. ncbi Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study
    Jens Jakob Thune
    Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    J Am Soc Echocardiogr 19:1462-5. 2006
    ..Regional assessment might be a more sensitive predictor of outcome than global assessment in patients with acute MI...
  21. ncbi Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events
    M A Pfeffer
    Department of Medicine, Brigham and Women s Hospital and Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 33:125-30. 1999
    ..We sought to assess the influence of baseline lipid levels on coronary event rates and the effectiveness of pravastatin therapy in the Cholesterol And Recurrent Events (CARE) study...
  22. ncbi High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    Rachel E Anderson
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
    Am Heart J 155:706-11. 2008
    ..We examined characteristics, cardiovascular outcomes, and the influence of risk factors on outcomes in young survivors of AMI...
  23. ncbi Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study
    Anil Verma
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    JACC Cardiovasc Imaging 1:582-91. 2008
    ..This study sought to understand prognostic implications of increased baseline left ventricular (LV) mass and geometric patterns in a high risk acute myocardial infarction...
  24. ncbi Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial)
    Satish Kenchaiah
    Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 94:1-8. 2004
    ..10). We conclude that antecedent hypertension is associated with subsequent LV dilation in patients after acute myocardial infarction with LV systolic dysfunction...
  25. ncbi Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats
    G F Mitchell
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 94:2923-9. 1996
    ..However, the pulsatile component of hemodynamic load has not been evaluated in this model...
  26. ncbi Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study
    S D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Ann Intern Med 134:451-8. 2001
    ..Nevertheless, recovery of ventricular function occurs in a significant proportion of patients after myocardial infarction, and modern reperfusion strategies have been associated with increased recovery of function...
  27. ncbi Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction
    Jens J Thune
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Hypertension 51:48-54. 2008
    ..Whether aggressive antihypertensive treatment can reduce this risk remains unknown...
  28. ncbi The CHARM program: study design leads to findings of clinical and public health importance
    Charles H Hennekens
    Florida Atlantic University, Boca Raton, Florida, and Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Cardiovasc Pharmacol Ther 12:124-6. 2007
    ..Such patients have a 50% mortality rate at 5 years, and heart failure is the leading cause of hospitalization for patients 65 years of age and older...
  29. ncbi Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease
    Marc S Sabatine
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 115:1528-36. 2007
    ....
  30. ncbi Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM
    Eldrin F Lewis
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur J Heart Fail 9:83-91. 2007
    ..Limited comparative studies assessing the health-related quality of life (HRQL) in heart failure (HF) patients with preserved vs. low ejection fraction (LVEF) have been disparate...
  31. ncbi VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context
    Eric J Velazquez
    Division of Cardiology, Department of Medicine, Duke University Medical Center and the Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715, USA
    Eur J Heart Fail 5:537-44. 2003
    ....
  32. ncbi A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study
    R Y L Zee
    Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215 1204, USA
    Clin Genet 61:21-5. 2002
    ....
  33. ncbi VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
    F M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Circulation 102:1886-92. 2000
    ..Plasma triglyceride concentration has been an inconsistent independent risk factor for coronary heart disease, perhaps because of the metabolic heterogeneity among VLDL particles, the main carriers of triglycerides in plasma...
  34. ncbi Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Rajesh Janardhanan
    Division of Cardiology, Brigham and Women's Hospital, Boston, MA02115, USA
    Am Heart J 152:183-9. 2006
    ..The observed risk was apparent even after excluding patients who had undergone revascularization...
  35. ncbi Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction
    Powell Jose
    Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Am Soc Nephrol 17:2886-91. 2006
    ..Monitoring serum creatinine in patients during the first few weeks after MI may help to identify those who are at highest risk and guide effective long-term therapeutic choices...
  36. ncbi C-reactive protein levels and outcomes after statin therapy
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 352:20-8. 2005
    ..Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown...
  37. ncbi The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study
    Anil Verma
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1238-45. 2007
    ..The purpose of this study was to determine whether alterations in cardiac structure or function contribute to the increased risk associated with renal impairment after myocardial infarction (MI)...
  38. ncbi Angiotensin-converting-enzyme inhibition in stable coronary artery disease
    Eugene Braunwald
    Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA
    N Engl J Med 351:2058-68. 2004
    ....
  39. ncbi Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02445, USA
    Circulation 112:3738-44. 2005
    ..Nevertheless, once elevated to a range above 45%, ejection fraction does not further contribute to assessment of cardiovascular risk in heart failure patients...
  40. ncbi Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both
    Sung Hee Shin
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 121:1096-103. 2010
    ..Mechanical dyssynchrony is considered an independent predictor for adverse cardiovascular outcomes in patients with heart failure. However, its importance as a risk factor after myocardial infarction is not well defined...
  41. ncbi Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study
    Eldrin F Lewis
    Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 42:1446-53. 2003
    ..Patients who experience late-onset HF have a 10-fold increased risk of death compared with other MI survivors. Baseline characteristics can risk stratify patients at high risk of subsequent HF...
  42. ncbi Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement
    M A Pfeffer
    Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts 02115
    Am J Hypertens 7:106S-111S. 1994
    ..These clinical observations point to an important potentially modifiable interface between the renin-angiotensin system and the risk of experiencing a coronary atherosclerotic event.(ABSTRACT TRUNCATED AT 250 WORDS)..
  43. ncbi Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 28:562-7. 2008
    ..The purpose of this study was to investigate the association between the Ala227Pro polymorphism in the ADAMTS1 metalloproteinase gene and coronary heart disease and benefit from statin therapy in 2 independent cohorts...
  44. ncbi Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction
    Hasan Jilaihawi
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 91:723-6. 2003
  45. ncbi Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators
    P M Ridker
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, The Children s Hospital Medical Center, Boston, MA, USA
    Circulation 100:230-5. 1999
    ..We evaluated whether long-term therapy with pravastatin, an agent that reduces cardiovascular risk, might alter levels of this inflammatory parameter...
  46. ncbi The heart and conduit vessels in hypertension
    G F Mitchell
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Med Clin North Am 81:1247-71. 1997
    ..This article reviews the adaptation of the heart and vessels to hypertension, the clinical implications of these structural and functional changes, and the effects of therapy on cardiovascular function...
  47. ncbi Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1495-504. 2004
    ..Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear...
  48. ncbi Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)
    Faisal Shamshad
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am Heart J 160:145-51. 2010
    ..Myocardial rupture is a relatively rare and usually fatal complication of myocardial infarction (MI). Early recognition of patients at greatest risk of myocardial rupture provides an opportunity for early intervention...
  49. ncbi Value of the electrocardiogram in predicting left ventricular enlargement and dysfunction after myocardial infarction
    Costantina Manes
    Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    Am J Med 114:99-105. 2003
    ..Predischarge ECG may be a useful tool for early identification of patients at risk of ventricular enlargement and persistent dysfunction following myocardial infarction...
  50. ncbi Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function
    Maria Amigoni
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Eur Heart J 28:326-33. 2007
    ....
  51. ncbi Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study
    Alessandra Meris
    Cardiovascular Division, Brigham and Women s Hospital, MA, USA
    Eur Heart J 30:56-65. 2009
    ..To assess the relationship between left atrial (LA) size and outcome after high-risk myocardial infarction (MI) and to study dynamic changes in LA size during long-term follow-up...
  52. ncbi Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction
    Leonardo A M Zornoff
    Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 39:1450-5. 2002
    ..3% to 29.2%; p = 0.006). CONCLUSIONS: Right ventricular function is an independent predictor of death and the development of HF in patients with LV dysfunction after MI...
  53. ncbi Predictors of heart failure in patients with stable coronary artery disease: a PEACE study
    Eldrin F Lewis
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circ Heart Fail 2:209-16. 2009
    ..The Prevention of Events with Angiotensin-Converting Enzyme Inhibition population enabled the development of a risk model to predict HF in patients with stable coronary artery disease and preserved ejection fraction...
  54. ncbi Increased pulse pressure and risk of heart failure in the elderly
    C U Chae
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02215 1204, USA
    JAMA 281:634-9. 1999
    ..Arterial stiffness increases with age. Thus, pulse pressure, an index of arterial stiffening, may predict congestive heart failure (CHF) in the elderly...
  55. ncbi Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance index--Survival and Ventricular Enlargement (SAVE) experience
    Nagesh S Anavekar
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Soc Echocardiogr 19:28-33. 2006
    ..The prognostic significance of MPI is less clear for cardiovascular (CV) events after myocardial infarction (MI) among individuals at high risk with depressed left ventricular (LV) systolic function...
  56. ncbi Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial
    George V Moukarbel
    Division of Cardiovascular Diseases, Department of Internal Medicine, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Eur Heart J 30:2226-32. 2009
    ..Risk factors for GI bleeding in post- myocardial infarction (MI) patients have not been well defined. We sought to identify risk factors for GI bleeding in patients following MI...
  57. ncbi Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program
    Akshay S Desai
    Department of Cardiology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1959-66. 2007
    ..We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients...
  58. ncbi Erythropoietic response and outcomes in kidney disease and type 2 diabetes
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 363:1146-55. 2010
    ..However, target-based strategies are confounded by each patient's individual hematopoietic response...
  59. ncbi Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 122:985-92. 2010
    ....
  60. ncbi Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 114:1028-35. 2006
    ..Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal adenomas but have been associated with increased cardiovascular risk...
  61. ncbi Variable impact of combining fatal and nonfatal end points in heart failure trials
    Hicham Skali
    Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 114:2298-303. 2006
    ..Longer-duration trials have a more predictable increase in events than short RCTs. Trial duration must be considered when composite end points are used during the design and interpretation of HF RCTs...
  62. ncbi Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors
    Frank M Sacks
    Nutrition Department, Harvard School of Public Health F M S, Boston, Mass 02115, USA
    Circulation 105:1424-8. 2002
    ..We conducted exploratory analyses of participant characteristics, lipid risk factors, and risk reduction in this group...
  63. ncbi Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study)
    Nagesh S Anavekar
    Department of Cardiology, Austin Health, University of Melbourne, Melbourne, Australia
    Am J Cardiol 101:607-12. 2008
    ..53 (95% CI 1.24 to 1.88) increased risk of fatal and nonfatal CV outcomes. In conclusion, decreased right ventricular systolic function is a major risk factor for death, sudden death, HF, and stroke after MI...
  64. ncbi Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:2687-93. 2007
    ..We assessed the association between albuminuria and the risks for death and cardiovascular events among patients with stable coronary disease...
  65. ncbi Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:1482-7. 2007
    ....
  66. ncbi Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Satish Kenchaiah
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 116:627-36. 2007
    ..However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality...
  67. ncbi Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 106:1251-5. 2002
    ..We used data from the Survival and Ventricular Enlargement (SAVE) echocardiographic substudy to test the hypothesis that diabetes was associated with increased LV enlargement after MI...
  68. ncbi Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 111:3411-9. 2005
    ....
  69. ncbi Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial
    Satish Kenchaiah
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 148:356-64. 2004
    ..Hypertension is a well-established risk factor for myocardial infarction (MI), but its prognostic importance in survivors of an acute MI is less clear...
  70. ncbi Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1071-80. 2005
    ..Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern...
  71. ncbi Cardiac remodeling in systemic hypertension
    Satish Kenchaiah
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Med Clin North Am 88:115-30. 2004
    ..Future targets of therapy in hypertensive heart disease may include regression of myocardial fibrosis, normalization of LA size, and improvement in LV diastolic function...
  72. ncbi Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction
    David Aguilar
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 43:2015-21. 2004
    ..We assessed the influence of alcohol intake on the development of symptomatic heart failure (HF) in patients with left ventricular (LV) dysfunction after a myocardial infarction (MI)...
  73. ncbi Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
    Am Heart J 150:257-62. 2005
    ..Angiotensin-converting enzyme (ACE) inhibition attenuates ventricular remodeling and improves ventricular function in heart failure patients. Vasopeptidase inhibition has shown similar effects in experimental models...
  74. ncbi Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1511-4. 2004
    ..To investigate the hypothesis that prior angina pectoris confers protection from remodeling occurring after myocardial infarction (MI), we analyzed echocardiograms from the Healing and Early Afterload Reducing Therapy (HEART) trial...
  75. ncbi Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 352:2581-8. 2005
    ..We assessed the risk and time course of sudden death in high-risk patients after myocardial infarction...
  76. ncbi Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)
    Jay N Cohn
    Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Eur J Heart Fail 5:659-67. 2003
    ....
  77. ncbi Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02445, USA
    Circulation 110:2180-3. 2004
    ..We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program...
  78. ncbi Left ventricular assessment in myocardial infarction: the VALIANT registry
    Adrian F Hernandez
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 165:2162-9. 2005
    ..41; P<.001). CONCLUSION: Left ventricular assessment was frequently not performed during the in-hospital stay of patients with acute MI, including those with clinical HF, and its use was associated with better quality of care...
  79. ncbi Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury
    O Eickmeier
    Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Mucosal Immunol . 2012
    ..Taken together, these findings indicate that AT-RvD1 displays potent mucosal protection and promotes catabasis after ALI.Mucosal Immunology advance online publication 11 July 2012. doi:10.1038/mi.2012.66...
  80. ncbi Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4
    A Planagumà
    Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Mucosal Immunol 3:270-9. 2010
    ....
  81. ncbi The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction
    P F Bray
    Department of Medicine, Thrombosis Research Section, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 88:347-52. 2001
    ..These data suggest that it would be important to perform a larger study to address the potential role of these genotypes in therapeutic decision making...
  82. ncbi Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage
    C F Opitz
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 32:261-7. 1998
    ..This study sought to delineate salvage-dependent from salvage-independent coronary reperfusion in acute myocardial infarction and the effects on spontaneously occurring arrhythmias and arrhythmic death in rats...
  83. ncbi Pulsatile hemodynamics in hypertension
    G F Mitchell
    Cardiovascular Engineering, Inc, Dover, Massachusetts, USA
    Curr Opin Cardiol 14:361-9. 1999
    ..A better understanding of abnormalities in pulsatile load in hypertension will facilitate risk stratification in and treatment of patients with hypertension...
  84. ncbi Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa
    R A P Weir
    Department of Cardiology, Western Infirmary, Glasgow, G11 6NT, United Kingdom Faculty of Medicine, University of Glasgow, United Kingdom
    Eur J Heart Fail 10:157-63. 2008
    ..The CHARM-Added trial describes the largest experience of using multiple inhibitors of the renin-angiotensin-aldosterone system (RAAS) together...
  85. ncbi Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease
    T-Christian H Mix
    Department of Development and Medical Affairs, Amgen Inc, Thousand Oaks, Calif, USA
    Am Heart J 149:408-13. 2005
    ..TREAT will provide data that are critical to evolution of the management of cardiovascular risk in this high-risk population...
  86. ncbi Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials
    James B Young
    Division of Medicine, The Cleveland Clinic Foundation and Kaufman Center for Heart Failure, 9500 Euclid Avenue T 13, Cleveland, OH 44195, USA
    Circulation 110:2618-26. 2004
    ..CHARM is a randomized, double-blind, placebo-controlled, multicenter, international trial program...
  87. ncbi Effect of pravastatin on cardiovascular events in people with chronic kidney disease
    Marcello Tonelli
    Division of Nephrology, University of Alberta, 7 129 Clinical Science Building, 8440 112 St, Edmonton, Alberta T6G 2G3, Canada
    Circulation 110:1557-63. 2004
    ..The objective of this analysis was to determine whether pravastatin reduced the incidence of cardiovascular events in people with or at high risk for coronary disease and with concomitant moderate CKD...
  88. ncbi Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy
    David Aguilar
    Division of Cardiology, University of Texas Health Science Center, Houston, 77030, USA
    Am J Cardiol 94:337-9. 2004
    ..During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs...
  89. ncbi Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy
    Tomas Berl
    University of Colorado Medical School, Denver, Colorado, USA
    Ann Intern Med 138:542-9. 2003
    ..004). CONCLUSION: The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy...
  90. ncbi Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction
    Lars Køber
    Department of Cardiology, Non Invasive Lab, Rigshospitalet, 9 Blegdamsvej, Copenhagen, Denmark
    Eur J Heart Fail 8:591-8. 2006
    ....
  91. ncbi Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program
    Tim Clayton
    Western Infirmary, Glasgow, UK
    Circulation 113:986-94. 2006
    ..In heart failure, the causes of anemia and the associations between anemia and outcomes are probably multiple and complex...
  92. ncbi Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    Salim Yusuf
    McMaster Clinic, Room 252, Hamilton General Hospital, 237 Barton Street East, ON, L8L 2X2, Hamilton, Canada
    Lancet 362:777-81. 2003
    ..We investigated the effect of addition of an angiotensin-receptor blocker to current treatments...
  93. ncbi Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    Christopher B Granger
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 362:772-6. 2003
    ..We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor...
  94. ncbi Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
    John J V McMurray
    University of Glasgow, Glasgow, UK
    Lancet 362:767-71. 2003
    ..We aimed to find out whether these drugs improve clinical outcome...
  95. ncbi Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both
    L Michael Prisant
    Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Am Coll Cardiol 51:1865-71. 2008
    ....
  96. ncbi Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction
    Alvaro M Murcia
    Mount Sinai Medical Center and Miami Heart Institute, Miami Beach, Fla, USA
    Arch Intern Med 164:2273-9. 2004
    ....
  97. ncbi Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, G12 8QQ, UK
    Circulation 110:3281-8. 2004
  98. ncbi Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Anique Ducharme
    Montreal Heart Institute, Montreal, Quebec, Canada
    Am Heart J 152:86-92. 2006
    ..CHARM provided the opportunity to prospectively determine the effect of candesartan on the incidence of new AF in this CHF population...
  99. ncbi Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program
    Lars G Olsson
    Department of Medicine, Sahlgrenska University Hospital/Ostra, , Sweden
    J Am Coll Cardiol 47:1997-2004. 2006
    ..CONCLUSIONS: Atrial fibrillation is associated with an increased risk of CV outcomes in patients with CHF and either reduced EF or PEF. Candesartan improved outcomes similarly regardless of baseline rhythm...
  100. ncbi Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland
    Am Heart J 151:985-91. 2006
    ..Whether an angiotensin receptor blocker is of benefit when added to a full dose of angiotensin-converting enzyme (ACE) inhibitor in heart failure (HF) is uncertain...
  101. ncbi Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 150:323-9. 2005
    ..The difference will be smaller or nonexistent in settings where brand-name ACE inhibitors are prescribed...